» Articles » PMID: 24966087

Chronic Kidney Disease: Targeting Prostaglandin E2 Receptors

Overview
Specialties Nephrology
Physiology
Date 2014 Jun 27
PMID 24966087
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic kidney disease is a leading cause of morbidity and mortality in the world. A better understanding of disease mechanisms has been gained in recent years, but the current management strategies are ineffective at preventing disease progression. A widespread focus of research is placed on elucidating the specific processes implicated to find more effective therapeutic options. PGE2, acting on its four EP receptors, regulates many renal disease processes; thus EP receptors could prove to be important targets for kidney disease intervention strategies. This review summarizes the major pathogenic mechanisms contributing to initiation and progression of chronic kidney disease, emphasizing the role of hyperglycemia, hypertension, inflammation, and oxidative stress. We have long recognized the multifaceted role of PGs in both the initiation and progression of chronic kidney disease, yet studies are only now seriously contemplating specific EP receptors as targets for therapy. Given the plethora of renal complications attributed to PG involvement in the kidney, this review highlights these pathogenic events and emphasizes the PGE2 receptor targets as options available to complement current therapeutic strategies.

Citing Articles

Urotensin II system in chronic kidney disease.

Michael O, Kanthakumar P, Soni H, Lenin R, Jha K, Gangaraju R Curr Res Physiol. 2024; 7:100126.

PMID: 38779598 PMC: 11109353. DOI: 10.1016/j.crphys.2024.100126.


Disruption of epithelium integrity by inflammation-associated fibroblasts through prostaglandin signaling.

Dong Y, Johnson B, Ruan L, Zeineldin M, Bi T, Liu A Sci Adv. 2024; 10(14):eadj7666.

PMID: 38569041 PMC: 10990275. DOI: 10.1126/sciadv.adj7666.


Urinary Prostaglandin E2 Excretion and the Risk of Cardiovascular and Kidney Disease.

Geurts F, Chaker L, van der Burgh A, Cronin-Fenton D, Fenton R, Hoorn E J Am Heart Assoc. 2024; 13(4):e032835.

PMID: 38362883 PMC: 11010119. DOI: 10.1161/JAHA.123.032835.


Tissue lipidomic profiling supports a mechanistic role of the prostaglandin E2 pathway for albuminuria development in glomerular hyperfiltration.

Kaiser-Graf D, Schulz A, Mangelsen E, Rothe M, Bolbrinker J, Kreutz R Front Netw Physiol. 2024; 3:1271042.

PMID: 38205443 PMC: 10777844. DOI: 10.3389/fnetp.2023.1271042.


Prostaglandin E2, Osmoregulation, and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.

Geurts F, Xue L, Kramers B, Zietse R, Gansevoort R, Fenton R Clin J Am Soc Nephrol. 2023; 18(11):1426-1434.

PMID: 37574650 PMC: 10637469. DOI: 10.2215/CJN.0000000000000269.